The stock of drug developer VIVUS, Inc. (NASDAQ:VVUS) got a hit from analysts at Piper Jaffray. VIVUS, Inc. (NASDAQ:VVUS) shares after opening at $5.81 moved to $5.83 on last trade day and at the end of the day closed at $5.42. Company price to sales ratio in past twelve months was calculated as 6.90 and price to cash ratio as 1.63. VIVUS, Inc. (NASDAQ:VVUS) showed a negative weekly performance of 5.24%.
Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) and Gentium S.p.A., announced the commencement of the European commercial launch of Defitelio (defibrotide), the first licensed product for the treatment of severe hepatic veno-occlusive disease (severe VOD or sVOD) in patients over one month of age undergoing haematopoietic stem cell transplantation (HSCT) therapy.1 The companies have launched Defitelio in Germany and Austria and expect to continue the launch in 27 additional European countries on a rolling basis during 2014 and 2015. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares fell 6.18% in last trading session and ended the day on $126.80. Jazz return on equity ratio is recorded as 17.70% and its return on assets is 10.10%. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) yearly performance is 131.98%.
Response Genetics, Inc. (NASDAQ:RGDX) reported to sign contracts with 6 additional healthcare plans across 10 states with which it raised its total contracted membership to around 174 million lives. Response Genetics, Inc. (NASDAQ:RGDX) shares moved down 9.15% in last trading session and was closed at $1.29, while trading in range of $ 1.26 – 1.50. Response Genetics, Inc. (NASDAQ:RGDX) year to date (YTD) performance is 11.21%.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) was the recipient of a large increase in short interest in January. As of March 14th, there was short interest totalling 18,148,887 shares, an increase of 24.6% from the February 28th total of 14,570,786 shares,American Banking News.com reports. Based on an average daily trading volume, of 4,913,757 shares, the days-to-cover ratio is currently 3.7 days. Approximately 34.2% of the shares of the company are sold short. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) weekly performance is -5.80%. On last trading day company shares ended up $4.06. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) distance from 50-day simple moving average (SMA50) is -25.25%. Analysts mean target Price for the company is $13.83.